Overcoming bortezomib resistance in multiple myeloma

Boldly Targeting Kinases without mutations

(2014) M. S. Davids   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

(2013) B. Y. Chang et al.   BLOOD

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia

(2013) S. A. Rushworth et al.   BLOOD

The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

(2013) Girija Dasmahapatra et al.   BRITISH JOURNAL OF HAEMATOLOGY

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

(2013) Robert Z. Orlowski   CANCER CELL

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

A Preclinical Assay for Chemosensitivity in Multiple Myeloma

(2013) Z. P. Khin et al.   CANCER RESEARCH

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

(2013) Jan A. Burger   Current Hematologic Malignancy Reports

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma

(2012) B. A. Walker et al.   BLOOD

The high Nrf2 expression in human acute myeloid leukemia is driven by NF- B and underlies its chemo-resistance

(2012) S. A. Rushworth et al.   BLOOD

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Bortezomib induces heme oxygenase-1 expression in multiple myeloma

(2012) Lawrence N. Barrera et al.   CELL CYCLE

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

(2012) Stuart A. Rushworth et al.   CELLULAR SIGNALLING

High Basal Nuclear Levels of Nrf2 in Acute Myeloid Leukemia Reduces Sensitivity to Proteasome Inhibitors

(2011) S. A. Rushworth et al.   CANCER RESEARCH

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

Bruton's Tyrosine Kinase Is Required for TLR-Dependent Heme Oxygenase-1 Gene Activation via Nrf2 in Macrophages

(2011) V. Vijayan et al.   JOURNAL OF IMMUNOLOGY

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms

(2010) E. De Bruyne et al.   BLOOD

Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia

(2010) K. Fiedler et al.   BLOOD

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial

(2010) A Dispenzieri et al.   LEUKEMIA

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation

(2008) Seoung Hoon Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH